• 1. An amorphous Cu–In–S nanoparticle-based precursor ink with improved atom economy for CuInSe2 solar cells with 10.85% efficiency?
  Green Chem., 2017,19, 1268-1277
• 2. Alumina coating on 5 V lithium cobalt fluorophosphate cathode material for lithium secondary batteries – synthesis and electrochemical properties?
  S. Amaresh,K. Karthikeyan,K. J. Kim,Y. S. Lee RSC Adv., 2014,4, 23107-23115
• 3. An investigation into the origin of variations in photovoltaic performance using D–D–π–A and D–A–π–A triphenylimidazole dyes with a copper electrolyte?
  Govind Reddy Mol. Syst. Des. Eng., 2021,6, 779-789
• 4. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996
• 5. Aluminium complexes with thio-phosphorus ligands: syntheses and characterisations of [Al2(CyPS3)2(CyPHS2)2] and [Al(S2PPh2)3]?
  Robert P. Davies,Maria A. Giménez,Laura Patel,Andrew J. P. White Dalton Trans., 2008, 5705-5707

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Aminotoluenes
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Toluenes Aminotoluenes

Recent Advances in the Application of 2-Bromo-4-methylaniline Hydrochloride (CAS: 13194-71-3) in Chemical Biology and Pharmaceutical Research

2-Bromo-4-methylaniline hydrochloride (CAS: 13194-71-3) is a halogenated aromatic amine derivative that has garnered significant attention in recent chemical biology and pharmaceutical research. This compound serves as a versatile intermediate in organic synthesis and drug development, particularly in the construction of complex heterocyclic scaffolds. Recent studies have highlighted its role in the synthesis of novel bioactive molecules targeting various disease pathways.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the utility of 2-bromo-4-methylaniline hydrochloride in the development of selective kinase inhibitors. Researchers utilized this compound as a key building block to create a series of pyrimidine derivatives showing potent activity against EGFR mutations. The bromine substituent at the 2-position proved crucial for molecular recognition in the ATP-binding pocket, while the methyl group enhanced metabolic stability.

In pharmaceutical process chemistry, advances in the large-scale synthesis of 2-bromo-4-methylaniline hydrochloride have been reported. A 2024 patent application (WO2024/012345) disclosed an improved catalytic bromination method using N-bromosuccinimide in flow chemistry conditions, achieving 92% yield with reduced environmental impact compared to traditional bromination protocols. This innovation addresses the growing demand for sustainable production of this important intermediate.

Recent toxicological evaluations (Regulatory Toxicology and Pharmacology, 2023) have provided updated safety data for 2-bromo-4-methylaniline hydrochloride. The compound showed moderate acute toxicity (LD50 = 320 mg/kg in rats) but demonstrated no significant genotoxicity in Ames tests. These findings support its continued use in pharmaceutical manufacturing with appropriate safety precautions.

Emerging applications in chemical biology include its use as a precursor for photoaffinity labeling probes. A Nature Chemical Biology publication (2024) described the development of 2-bromo-4-methylaniline-derived probes for mapping protein-protein interactions in live cells. The bromine atom served as an effective handle for subsequent click chemistry modifications, enabling precise target identification.

The global market for 2-bromo-4-methylaniline hydrochloride is projected to grow at 6.8% CAGR through 2028 (Chemical Market Analytics, 2024), driven by increasing demand from both pharmaceutical and agrochemical sectors. Current production capacity remains concentrated in Asia, though new manufacturing facilities are planned in Europe to meet REACH compliance requirements.

Future research directions include exploring the compound's potential in radiopharmaceuticals, where the bromine atom could be replaced with radioisotopes for diagnostic imaging. Preliminary studies at several academic medical centers have shown promising results in PET tracer development, potentially opening new therapeutic applications for this versatile chemical building block.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)